Klow is a physician-prescribed compounded blend of four peptides: GHK-Cu, which supports collagen production and tissue remodeling; KPV, a tripeptide derived from alpha-melanocyte-stimulating hormone that calms inflammatory signaling without broadly suppressing the immune system; and BPC-157 and TB-500, which support tissue repair beneath the surface. The four peptides work through different mechanisms, so combining them is meant to cover ground no single one would.

KPV calms the inflammatory signaling that can interfere with tissue repair. GHK-Cu stimulates collagen synthesis and supports dermal remodeling and antioxidant response. BPC-157 promotes repair at sites of tissue damage, and TB-500 circulates systemically to support cell migration and remodeling. Together, the blend targets inflammation, structural rebuilding, and deep tissue repair as connected processes, supporting overall skin resilience and, for some patients, hair follicle health.

People with visible signs of skin aging who also deal with chronic skin inflammation, those who want both collagen support and inflammation control in one protocol, people with hair thinning who also want inflammation support, and those seeking a more comprehensive approach to skin resilience than a single-peptide protocol.

Many patients report early calming of skin inflammation within the first one to two weeks, reflecting KPV's effect on inflammatory signaling. Improvements in firmness and fine lines typically follow over the next two to six weeks as GHK-Cu supports collagen and remodeling. Hair-related benefits tend to take longer, often several months. Klow can be administered topically, subcutaneously, or as a combination, depending on your goals, as determined by Dr. Taylor.

Commonly reported side effects include mild skin irritation, injection site redness or irritation, rare temporary skin discoloration, rare mild gastrointestinal discomfort (with oral KPV), and, less often, nausea, headache, or temporary fatigue. Klow is not appropriate with active cancer or a history of malignancy, during pregnancy or breastfeeding, with copper sensitivity or Wilson disease, with hypersensitivity to alpha-MSH-derived peptides, with active skin infections at the application site, with active liver or kidney disease, alongside immunosuppressive therapy without guidance, alongside anticoagulants without supervision, or with a family history of stomach or colon cancer. These peptides are not FDA-approved as a combined therapy; Klow is prescribed off-label under physician supervision after intake and informed consent.